Hudson Bay Capital Management LP Altimmune, Inc. Transaction History

Hudson Bay Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $181,188 - $341,024	20,731 New	20,731 $341,000
Q3 2020 Nov 12, 2020	SELL	$9.93 - $33.26 $7.75 Million - $25.9 Million	-780,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$2.9 - $10.71 $2.26 Million - $8.35 Million	780,000 New	780,000 $8.35 Million
Q2 2019 Aug 14, 2019	SELL	$2.19 - $3.4 $573,355 - $890,140	-261,806 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.54 - $4.54 $664,987 - $1.19 Million	261,806 New	261,806 $759,000
Q4 2018 Feb 13, 2019	SELL	$1.72 - $7.24 $86,000 - $362,000	-50,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$4.27 - $26.23 $213,499 - $1.31 Million	50,000 New	50,000 $220,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $428M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.